B+
Bull case
25%
Probability
Target price
$14.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
CLYM
Climb BioFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Primary company sources support a genuinely catalyst-rich 2026: subcutaneous budoprutug data in H1 2026, initial CLYM116 healthy-volunteer data in mid-2026, and first budoprutug data from pMN, ITP, and SLE studies in H2 2026, while cash, cash equivalents, and marketable securities of $160.7 million at December 31, 2025 are expected to fund operations into 2028 [#PR-2026-03-05].
Posture
Defensive
Lead driver
Value
What changed
1 setup hits (3d) with net bullish as of 2026-09-09.
What can break
Clinical readouts in 2026 could miss on efficacy, PK/PD translation, or tolerability.
Momentum
94
Value
41
Sentiment
13
Setup hits (3d)
1 · Net Bullish
AI TargetsBase $8.50 · Bull $14.00 · Bear $5.00Analysis 2026-04-15; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Bullish
Target $27.47
Why
Momentum94 · Δ7d +0.3
Value41 · Δ7d 0.0
Sentiment13 · Δ7d -2.2
So what
Weak posture (Net Bullish). Prioritize risk control and patience.
Confirming evidence
- • 1 setup hits (3d) with net bullish as of 2026-09-09.
- • Value remains the lead driver in the composite, 7D delta 0.0.
Contradictions & invalidation
- • Clinical readouts in 2026 could miss on efficacy, PK/PD translation, or tolerability.
- • Despite runway guidance into 2028, sustained operating losses mean financing risk can return quickly if timelines slip or studies expand.
- • This remains a low-coverage, early-stage biotech with no approved products, continuing losses, and a thesis still dependent on unreleased 2026 data.
Catalyst clock
2026-05-05
May 5, 2026 budoprutug R&D spotlight can refine expectations but is mainly narrative
Lead driver: Value · See fundamentals
Momentum
94
9% active weight
Current posture
7d trendImproving
Δ7d
+0.3
Δ21d
-1.6
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
13
62% active weight
Current posture
7d trendSoftening
Δ7d
-2.2
Δ21d
+8.4
Why this grade
Composite grade F. Momentum 94.4 / Value 41.2 / Sentiment 12.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-15. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$8.50
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$5.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$1B
Beta
-0.15
Shares Out
57.44M
P/E (TTM) · Derived
-19.8
P/S (TTM)
-
P/FCF (TTM) · Derived
-22.80
Rev YoY
-
EPS YoY
+38.2%
Gross Margin
-
Op Margin
-
Net Debt
-$100.54M
Current Ratio
31.45
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data